marginal zone lymphoma
Brukinsa Granted Accelerated Approval for Treatment of R/R MZL
The FDA granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) for adults with relapsed or refractory ...
OCTOBER 14, 2021
FDA Grants Accelerated Approval to Ukoniq for Previously Treated MZL and FL
The FDA approved umbralisib (Ukoniq, TG Therapeutics) for adults with relapsed or refractory marginal zone lymphoma ...
FEBRUARY 18, 2021
Revlimid-Rituximab Combo Approved for FL and MZL
The FDA approved lenalidomide (Revlimid, Celgene) in combination with a rituximab product for previously treated ...
JUNE 4, 2019
Load more